GLOBAL MED TECHNOLOGIES® DELIVERS RECORD SECOND QUARTER AND FIRST HALF REVENUES
First Half and Q2 Revenues Rose 20.5% and 17.7%, Respectively*

Q2 Marked by Series of Watershed Events and Critical Developments

16 th Consecutive Quarter of Comparable Quarter-to-Quarter Revenue Growth

Global Med Technologies®, Inc. (“Global Med” or the “Company”) (OTCBB: GLOB), an international e-Health, medical information technology company, today reported record revenues for the three and six months ended June 30, 2008.

Highlighted by a strong series of events that included: a multimillion dollar contract with Utah’s largest healthcare provider; a strategic alliance with Cerner Corporation, including a contract with Egyptian Children’s Cancer Hospital Foundation; a national agreement with the American Red Cross to regionally license Global Med software; an agreement with Siemens to license software to California’s famed Riverside County Regional Medical Center serving the state’s fourth largest population center; similar agreements with St. Joseph’s Healthcare System and CentraState Healthcare System, both of New Jersey; all crowned by the acquisition of its European counterpart, Inlog, SA with $11.1 million in revenues and EBITDA of $574 thousand – extending Global Med’s total reach to over 1,500 sites across 20 countries. Global Med’s 2008 six month revenues* climbed from $7.69 million to $9.26 million, up $1.57 million or 20.5%, and second quarter revenues* rose from $3.97 million in 2007 to $4.67 million, an increase of $702,000 or 17.7%. Operating income* was $975,000 and $642,000 for the first half 2008 and 2007, respectively, and $350,000 and $346,000 for the quarter ended June 30, 2008 and 2007, respectively. Net income* was $529,000 for the first half of 2008 and $169,000 for the quarter. All numbers are exclusive of Inlog, which was acquired five days prior to the end of the second quarter.

Recurring annual maintenance revenues, exclusive of Inlog, for the quarter were running at an annualized rate of over $8 million. Based on backlog as of June 30, 2008, the Company’s annual recurring revenues, when all contracted customer sites are implemented, will be approximately $9.6 million, exclusive of Inlog. Exclusive of Inlog, the Company’s backlog of unrecognized software license fees and implementation fees was approximately $5.5 million.

The second quarter’s results marked the 16 th consecutive quarter of comparable quarter-to-quarter revenue growth for the Company.

On July 31, 2008, the Company acquired eDonor, a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers, for total consideration of $5 million in cash and stock. The acquisition was executed in the form of an asset purchase and is designed to complement Global Med’s strong line of international blood management and laboratory information software and service solutions.

Mick Ruxin, M.D., Chairman and CEO of Global Med Technologies, Inc., commenting on the recent acquisitions and quarterly results, stated, “The Company’s acquisition of Inlog and eDonor will be transformative events. While Global Med expects organic revenues to continue to grow at double digit rates throughout the remainder of the year, Inlog’s and eDonor’s revenues will substantially increase the Company’s overall revenues beginning in the third quarter of 2008. The acquisition of Inlog has provided the Company with an avenue to quickly enter the European market, and the Company has already identified a number of cross-selling opportunities.”

Thomas F. Marcinek, the Company’s President and COO, stated, “Global Med continues to execute on its business plan. The Company’s acquisition of Inlog will bring with it many opportunities for continued growth. For example, Inlog’s EdgeCell cellular therapy software has applications for tissue banks and stem cell centers in the United States.” Mr. Marcinek continued, “The Company’s revenues are at record levels and our second quarter’s annualized recurring maintenance revenues were in excess of $8 million (exclusive of Inlog’s recurring revenues); this is nearly $1.4 million higher than the comparable quarter of 2007. eDonor’s product and service offerings complement the Company’s ElDorado Donor ™ product.”

The Company will host a conference call today at 4:30 p.m. EDT. Mick Ruxin, M.D., Chief Executive Officer, Tom Marcinek, President and Chief Operating Officer, and Darren Craig, Acting CFO, will discuss the second quarter financial results and will be available to answer questions. Interested parties are welcome to call the following telephone numbers five minutes prior to the start of the conference call. Callers within the US should call: 1-866-789-9224. Callers that are outside of the US should call: 1-706-679-9621. Callers should reference "Global Med Second Quarter Financial Results" to the conference call operator. The conference call ID number will be: 58996634.

 An automated replay of the conference call will be available from August 12, 2008 at 5:30 p.m. EDT until August 14, 2008 at 11:59 p.m. EDT. To access the replay, callers within the US should call: 1-800-642-1687. Callers outside of the US should call: 1-706-645-9291 and enter Global Med’s access code of 58996634. The replay of the conference call will be available from August 14, 2008 onward at Global Med’s website at www.globalmedtech.com .

The following tables provide information related to the Company's operations for the three and six months ended June 30, 2008 and 2007 which excludes Inlog’s results for the acquisition period:

GLOBAL Med Technologies, Inc.
(OTC Bulletin Board: GLOB.OB)
(EXCLUDES INLOG)**
Selected Results
Three Months Ended June 30,
In (000s) Except Per Share Information
(Unaudited)  

Global Med Technologies, Inc.
(OTC Bulletin Board: GLOB.OB)
(EXCLUDES INLOG)**
Selected Results
Six Months Ended June 30,
In (000s) Except Per Share Information
(Unaudited)

Global Med Technologies, Inc. CONSOLIDATED
(OTC Bulletin Board: GLOB.OB)
(INCLUDES INLOG)
Selected Results
June 30, 2008
In (000s) Except Per Share Information
(Unaudited)

About Global Med Technologies, Inc.

Global Med Technologies®, Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med’s products are deployed in 20 countries and serve over 1,500 transfusion centers, blood banks and laboratories.

Global Med’s U.S. division, Wyndgate Technologies®, provides Vein-to-Vein® tracking through its Donor Doc™, SafeTrace®, SafeTrace Tx® and ElDorado Donor™ software products. Each year, Wyndgate’s products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply.

Global Med’s European subsidiary, Inlog, SA, is a leading provider of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog’s products include EdgeBlood****, EdgeTrack****, EdgeCell, EdgeLab and SAPA.

Global Med’s U.S. division, eDonor®, provides a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers and hospitals. eDonor’s products and services are designed to complement Global Med’s strong line of international blood management and laboratory information software and service solutions.

Global Med’s U.S. subsidiary, PeopleMed®, Inc., provides cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers. 

*Excludes Inlog’s revenues of $174 thousand on a pro rata basis. Also excludes Inlog’s cost of revenues, operating expenses, other income (expenses), taxes, and net income for the three and six months ended June 30, 2008. On a consolidated basis, the Company’s revenues increased $876 thousand or 22.1% to $4.845 million or $1.750 million or 22.8% to $9.438 million for the three and six months ended 2008, respectively.

**Inlog’s results for the five-day period ended June 30, 2008 have been excluded from this analysis in order to provide the reader with a mechanism for comparing the Company’s organic results for the three and six months ended June 30, 2008 with the historical results for the comparable periods in 2007. The Company believes this information is useful to readers to better enable them to understand the Company’s performance.

The Company’s cash balance of $8.165 million includes Inlog’s cash balance of $1.572 million as of June 30, 2008.

***For the three and six months ended June 30, 2007, the Company recognized approximately $80 thousand in accrued interest related to the return of a deposit in escrow of $1.004 million which increased the Company’s cash flows from operations by $1.084 million.

****FDA 510(k) clearance required prior to sales in the U.S.